Heavis

Heavis is an oral medication whose active ingredient is cytisinicline, a nicotinic acetylcholine receptor partial agonist marketed in the European Union. The product is formulated for delivery and is intended to support adults who are trying to quit smoking. Cytisinicline works by modulating α4β2 receptors, helping to lessen withdrawal symptoms and cravings associated with nicotine dependence. It is supplied without a specified strength and its dosage form is not disclosed.

Heavis is indicated for adults who wish to discontinue tobacco use and is used as part of a comprehensive smoking‑cessation program.

- As a stand‑alone pharmacologic aid for quitting smoking. - In combination with behavioral counseling. - For individuals who have experienced difficulty with nicotine‑replacement therapies. - To reduce nicotine withdrawal symptoms such as irritability, anxiety, and cravings. - May be considered when other approved cessation medications are contraindicated.

The safety profile of Heavis reflects its activity at nicotinic receptors; reported adverse events are generally mild to moderate.

Common: - Nausea - Headache - Dry mouth - Insomnia - Dizziness

Serious: - Severe allergic reaction (anaphylaxis) - Persistent cardiovascular symptoms (e.g., palpitations, hypertension) - Psychiatric disturbances (e.g., mood swings, depression) - Respiratory distress - Seizures

Clinicians should evaluate patient history and current health status before prescribing Heavis to ensure safe use.

- Assess for known hypersensitivity to cytisinicline or related compounds. - Use caution in patients with cardiovascular disease or uncontrolled hypertension. - Evaluate psychiatric history, especially depression or anxiety disorders. - Consider renal or hepatic impairment, as clearance data are limited. - Advise pregnant or breastfeeding individuals to discuss potential risks with a healthcare professional. - Review concurrent use of other nicotine‑related products.

Heavis may interact with other medications that influence nicotinic receptors or central nervous system activity.

Avoid: - Concomitant use of other nicotinic agonists (e.g., nicotine replacement therapy, varenicline). - Monoamine oxidase inhibitors (MAOIs) due to potential additive CNS effects. - Strong CYP450 inhibitors if metabolic pathway identified (pending data).

Use with caution: - CNS depressants such as benzodiazepines or opioids. - Antidepressants, particularly SSRIs, that may affect mood regulation. - Antihypertensive agents, as blood pressure changes have been reported.